Clarity Pharmaceuticals Ltd
CU6
Rank in Stocks
#13055
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The companyโs lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Share Price
$1.12
Last synced: 2026-11-10
Market Cap
$418.35M
Change (1 day)
2.21%
Change (1 year)
-62.81%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Clarity Pharmaceuticals Ltd (CU6)
Category
Healthcare
Operating Margin for Clarity Pharmaceuticals Ltd (CU6)
Operating Margin as of November 2026 TTM: 0.00%
According to Clarity Pharmaceuticals Ltd's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -730.16%.
Operating Margin history for Clarity Pharmaceuticals Ltd from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -730.16% | 87.53% |
| 2024 | -389.35% | 5.51% |
| 2023 | -369.00% | 39.80% |
| 2022 | -263.94% | -37.55% |
| 2021 | -422.65% | 19.71% |
| 2020 | -353.06% | 45.62% |
| 2019 | -242.45% | 42.06% |
| 2018 | -170.67% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 18.91% | - |
IE
|
|
| 10.95% | - |
CN
|
|
| 25.26% | - |
CH
|
|
| 13.54% | - |
CH
|
|
| 38.62% | - |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Clarity Pharmaceuticals Ltd's operating margin
What was Clarity Pharmaceuticals Ltd's operating margin in 2025?
In 2025, Clarity Pharmaceuticals Ltd's operating margin was -730.16%, compared with -389.35% in 2024.
How has Clarity Pharmaceuticals Ltd's operating margin changed since 2020?
From 2020 to 2025, Clarity Pharmaceuticals Ltd's operating margin was highest in 2022 (-263.94%) and lowest in 2025 (-730.16%).
How does Clarity Pharmaceuticals Ltd's operating margin compare with similar companies?
Clarity Pharmaceuticals Ltd's operating margin (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Jafron Biomedical Co.,Ltd., with 38.62%.